ABSTRACT We have developed an open-source pipeline for the analysis of Spitzer/IRAC channel 1 and 2 time-series photometry, incorporating some of the most popular decorrelation methods. We applied this pipeline to new phase curve observations of ultra-hot Jupiters MASCARA-1b and KELT-16b, and we performed the first comprehensive reanalysis of 15 phase curves. We find that MASCARA-1b and KELT-16b have phase offsets of $6^{+11}_{-11}~^{\circ }$W and $38^{+16}_{-15}~^{\circ }$W, dayside temperatures of $2952^{+100}_{-97}$  and $3070^{+160}_{-150}$ K, and nightside temperatures of $1300^{+340}_{-340}$ and $1900^{+430}_{-440}$ K, respectively. We confirm a strong correlation between dayside and irradiation temperatures with a shallower dependence for nightside temperature. We also find evidence that the normalized phase curve amplitude (peak-to-trough divided by eclipse depth) is correlated with stellar effective temperature. In addition, while our different models often retrieve similar parameters, significant differences occasionally arise between them, as well as between our preferred model and the literature values. Nevertheless, our preferred models are consistent with published phase offsets to within −8 ± 21 degrees (−1.6 ± 3.2 sigma), and normalized phase curve amplitudes are on average reproduced to within −0.01 ± 0.24 (−0.1 ± 1.6 sigma). Finally, we find that BLISS performs best in most cases, but not all; we therefore recommend future analyses consider numerous detector models to ensure an optimal fit and to assess model dependencies.

Background and aims

ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA).

Approach and results

Patients were randomized 1:1:1 to oral seladelpar 5 mg (n=89), 10 mg (n=89), placebo (n=87) daily (with UDCA, as appropriate). Primary end point was a composite biochemical response [alkaline phosphatase (ALP) < 1.67×upper limit of normal (ULN), ≥15% ALP decrease from baseline, and total bilirubin ≤ ULN] at month 12. Key secondary end points were ALP normalization at month 12 and change in pruritus numerical rating scale (NRS) at month 6 in patients with baseline score ≥4. Aminotransferases were assessed. ENHANCE was terminated early following an erroneous safety signal in a concurrent, NASH trial. While blinded, primary and secondary efficacy end points were amended to month 3. Significantly more patients receiving seladelpar met the primary end point (seladelpar 5 mg: 57.1%, 10 mg: 78.2%) versus placebo (12.5%) ( p < 0.0001). ALP normalization occurred in 5.4% ( p =0.08) and 27.3% ( p < 0.0001) of patients receiving 5 and 10 mg seladelpar, respectively, versus 0% receiving placebo. Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 ( p =0.02); placebo: -1.55]. Alanine aminotransferase decreased significantly with seladelpar versus placebo [5 mg: 23.4% ( p =0.0008); 10 mg: 16.7% ( p =0.03); placebo: 4%]. There were no serious treatment-related adverse events.

Conclusions

Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. Seladelpar appeared safe and well tolerated.

We are now on a clear trajectory for improvements in exoplanet observations that will revolutionize our ability to characterize their atmospheric structure, composition, and circulation, from gas giants to rocky planets. However, exoplanet atmospheric models capable of interpreting the upcoming observations are often limited by insufficiencies in the laboratory and theoretical data that serve as critical inputs to atmospheric physical and chemical tools. Here we provide an up-to-date and condensed description of areas where laboratory and/or ab initio investigations could fill critical gaps in our ability to model exoplanet atmospheric opacities, clouds, and chemistry, building off a larger 2016 white paper, and endorsed by the NAS Exoplanet Science Strategy report. Now is the ideal time for progress in these areas, but this progress requires better access to, understanding of, and training in the production of spectroscopic data as well as a better insight into chemical reaction kinetics both thermal and radiation-induced at a broad range of temperatures. Given that most published efforts have emphasized relatively Earth-like conditions, we can expect significant and enlightening discoveries as emphasis moves to the exotic atmospheres of exoplanets.